Literature DB >> 11568021

Very long-term results (more than 20 years) of valve repair with carpentier's techniques in nonrheumatic mitral valve insufficiency.

E Braunberger1, A Deloche, A Berrebi, F Abdallah, J A Celestin, P Meimoun, G Chatellier, S Chauvaud, J N Fabiani, A Carpentier.   

Abstract

BACKGROUND: Mitral valve repair is considered the gold standard in surgery of degenerative mitral valve insufficiency (MVI), but the long-term results (>20 years) are unknown. METHODS AND
RESULTS: We reviewed the first 162 consecutive patients who underwent mitral valve repair between 1970 and 1984 for MVI due to nonrheumatic disease. The cause of MVI was degenerative in 146 patients (90%) and bacterial endocarditis in 16 patients (10%). MVI was isolated or, in 18 cases, associated with tricuspid insufficiency. The mean age of the 162 patients (104 men and 58 women) was 56+/-10 years (age range 22 to 77 years). New York Heart Association functional class was I, II, III, and IV in 2%, 39%, 52%, and 7% of patients, respectively. The mean cardiothoracic ratio was 0.58+/-0.07 (0.4 to 0.8), and 72 (45%) patients had atrial fibrillation. Valve analysis showed that the main mechanism of MVI was type II Carpentier's functional classification in 152 patients. The leaflet prolapse involved the posterior leaflet in 93 patients, the anterior leaflet in 28 patients, and both leaflets in 31 patients. Surgical technique included a Carpentier's ring annuloplasty in all cases, a valve resection in 126 patients, and shortening or transposition of chordae in 49 patients. During the first postoperative month, there were 3 deaths (1.9%) and 3 reoperations (2 valve replacements and 1 repeat repair [1.9%]). Six patients were lost to follow-up. The remaining 151 patients with mitral valve repair were followed during a median of 17 years (range 1 to 29 years; 2273 patient-years). The 20-year Kaplan-Meier survival rate was 48% (95% CI 40% to 57%), which is similar to the survival rate for a normal population with the same age structure. The 20-year rates were 19.3% (95% CI 11% to 27%) for cardiac death and 26% (95% CI 17% to 35%) for cardiac morbidity/mortality (including death from a cardiac cause, stroke, and reoperation). During the 20 years of follow-up, 7 patients were underwent surgery at 3, 7, 7, 8, 8, 10, or 12 years after the initial operation. Valve replacement was carried out in 5 patients, and repeat repair was carried out in 2 patients. At the end of the study, 65 patients remained alive (median follow-up 19 years). Their median age was 76 years (age range 41 to 95 years). All except 1 were in New York Heart Association functional class I/II.
CONCLUSIONS: Mitral valve repair using Carpentier's technique in patients with nonrheumatic MVI provides excellent long-term results with a mortality rate similar to that of the general population and a very low incidence of reoperation.

Entities:  

Mesh:

Year:  2001        PMID: 11568021

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  89 in total

1.  Current status of percutaneous valvular procedures.

Authors:  Dominique Himbert; Eric Brochet; David Messika-Zeitoun; Alec Vahanian
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-11

Review 2.  Contemporary application of the edge-to-edge repair.

Authors:  Alberto Pozzoli; Luca Vicentini; Michele De Bonis; Giovanna Di Giannuario; Giovanni La Canna; Ottavio Alfieri
Journal:  Ann Cardiothorac Surg       Date:  2015-07

3.  Lifting posterior mitral annuloplasty for enhancing leaflet coaptation in mitral valve repair: midterm outcomes.

Authors:  Meong Gun Song; Je Kyoun Shin; Hyun Keun Chee; Jun Seok Kim; Hyun Suk Yang; Jong Bum Choi
Journal:  Ann Cardiothorac Surg       Date:  2015-05

Review 4.  Minimally invasive mitral valve repair using a semi-rigid annuloplasty ring with a new chordal sizing system: the Memo3D ReChord.

Authors:  Mattia Glauber; Matteo Ferrarini; Antonio Miceli
Journal:  Ann Cardiothorac Surg       Date:  2015-05

Review 5.  Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system.

Authors:  P Boekstegers; J Hausleiter; S Baldus; R S von Bardeleben; H Beucher; C Butter; O Franzen; R Hoffmann; H Ince; K H Kuck; V Rudolph; U Schäfer; W Schillinger; N Wunderlich
Journal:  Clin Res Cardiol       Date:  2014-02       Impact factor: 5.460

Review 6.  Leakage test during mitral valve repair.

Authors:  Taiju Watanabe; Hirokuni Arai
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-08-27

Review 7.  Mitral valve repair: better than replacement.

Authors:  J M Ferrão de Oliveira; Manuel J Antunes
Journal:  Heart       Date:  2006-02       Impact factor: 5.994

Review 8.  Current concepts in mitral valve repair for degenerative disease.

Authors:  David H Adams; Anelechi C Anyanwu; Parwis B Rahmanian; Farzan Filsoufi
Journal:  Heart Fail Rev       Date:  2006-09       Impact factor: 4.214

9.  Ex Vivo Methods for Informing Computational Models of the Mitral Valve.

Authors:  Charles H Bloodworth; Eric L Pierce; Thomas F Easley; Andrew Drach; Amir H Khalighi; Milan Toma; Morten O Jensen; Michael S Sacks; Ajit P Yoganathan
Journal:  Ann Biomed Eng       Date:  2016-10-03       Impact factor: 3.934

10.  Reoperation in mitral valve repair for regurgitant mitral valve disease.

Authors:  Masato Nakajima; Kouji Tsuchiya; Hideki Sasaki; Narutoshi Hibino; Yuji Naito; Hidenori Inoue; Eiki Mizutani
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.